| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | VTX3232 | Obesity and cardiometabolic risk factors | Phase 2 | Data Released | Oral | Endocrinology |
| Eli Lilly and Company | Tirzepatide - (SURMOUNT-4) | Obesity or overweight with weight-related comorbidities | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Mirikizumab - (VIVID-2) | Crohn's disease | Phase 2 | Data Released | Intravenous | Gastroenterology |
| Eli Lilly and Company | Olomorasib | KRAS G12C-mutant advanced solid tumors | Phase 3 | Ongoing | Oral | Oncology |
| Eli Lilly and Company | Insulin efsitora alfa (efsitora) - (QWINT-3) | Type 2 diabetes | Phase 3 | Data Released | Subcutaneous injection | Endocrinology |
| Eli Lilly and Company | Insulin efsitora alfa (efsitora) - (QWINT-5) | Type 2 diabetes | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Tirzepatide - (SURMOUNT-3) | Obesity or overweight with weight-related comorbidities | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Elicio Therapeutics Inc. | ANG-3070 | Idiopathic Pulmonary Fibrosis | Phase 2 | Trial Discontinued | oral | Respiratory |